ViaCyte Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • ViaCyte's estimated annual revenue is currently $20M per year.(i)
  • ViaCyte received $80.0M in venture funding in November 2018.
  • ViaCyte's estimated revenue per employee is $188,632
  • ViaCyte's total funding is $289.5M.

Employee Data

  • ViaCyte has 106 Employees.(i)
  • ViaCyte grew their employee count by -15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments that will reduce or eliminate the need for blood glucose monitoring, insulin administration, and the risks of hypoglycemia and diabetes-related complications. ViaCyte has two products in clinical development. The first is called the PEC-Direct product candidate, which delivers proprietary pancreatic progenitor cells (PEC-01 cells) in a non-immunoprotective device. The PEC-Direct product candidate is being developed for type 1 diabetes (T1D) patients who have hypoglycemia unawareness, recurrent severe hypoglycemic episodes, and/or extreme glycemic lability.  The second product is called the PEC-Encap (also known as VC-01) product candidate. The PEC-Encap product candidate delivers pancreatic progenitor cells in an immunoprotective device and is being developed as a potential therapy for all diabetes patients who use insulin to control their disease.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





ViaCyte News

2022-04-17 - ViaCyte to Participate in 2022 Advanced Technologies ...

ViaCyte is a clinical-stage cellular therapy company with an advanced stem cell platform that delivers therapeutic proteins to restore health in...

2022-04-17 - Paul Laikind, PhD, Joins Stemson Therapeutics Board of ...

Paul Laikind, PhD, was CEO of ViaCyte from 2012 until 2020, where he lead the development of the first stem cell-derived cell therapies...

2022-03-22 - Stem cells may finally offer a cure for Type 1 diabetes

Other global companies are also working to cure diabetes, such as ViaCyte, CRISPR, and Novo Nordisk, one of the biggest insulin...

2021-06-30 - ViaCyte Raises $115 Million Series D

ViaCyte, a clinical stage biotech company, has raised $115 million in Series D financing, to bring forward two phase 2 studies of type 1 diabetes candidates. Michael Yang, President and CEO, ViaCyte The round includes participation from existing investors Bain Capital Life Sciences, TPG Capital ...

2021-06-19 - ViaCyte Raises $45M in Funding

ViaCyte, a San Diego CA-based regenerative medicine company, raised $45M in Series D funding. The round, which brought total Series D to more than $115m, includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Cap ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

ViaCyte Funding

DateAmountRoundLead InvestorsReference
2001-12-19$4.0MStrategic InvestmenSurModicsArticle
2007-07-17$25.0MCJohnson and Johnson DevelopmenArticle
2014-08-26$20.0MUndisclosedJanssen Research & Development LLCArticle
2017-05-23$10.0MUndisclosedAsset Management Partners,Article
2018-11-30$80.0MDBain Capital Life SciencesArticle